Loading...
•
Sep 30, 2024
Tempest Q3 2024 Earnings Report
Tempest Therapeutics reported financial results for the quarter ended September 30, 2024 and provided a corporate update.
Key Takeaways
Tempest Therapeutics reported a net loss of $10.6 million for the third quarter of 2024. The company ended the quarter with $22.1 million in cash and cash equivalents. They also received a 'Study May Proceed' letter from the FDA for their pivotal Phase 3 trial of amezalpat combination therapy.
Received FDA 'Study May Proceed' letter for pivotal Phase 3 trial of amezalpat combination therapy to treat first-line HCC.
Announced agreement with Roche to support advancement of amezalpat into first-line HCC pivotal Phase 3 trial.
Received final funding approval from NCI to move TPST-1495 into a Phase 2 trial in FAP.
Expanded leadership team to strengthen global clinical expertise.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...